Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48321 - hepatitis b virus surface antigen ivd, kit, chemiluminescent immunoassay - liaison? xl murex hbsag quant assay uses chemiluminescence immunoassay (clia) technology for the quantitative determination of hepatitis b surface antigen (hbsag) in human serum or plasma samples. for the quantitative determination of hepatitis b surface antigen (hbsag) in human serum and plasma samples, including specimens collected up to 24 hours post-mortem (non-heart beating).

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48366 - hepatitis c virus total antibody ivd, kit, chemiluminescent assay - the liaison? xl murex hcv ab assay uses chemiluminescence immunoassay (clia) technology for the qualitative determination of specific antibodies to hepatitis c virus (anti-hcv) in human serum or plasma samples. the test has to be performed on the liaison? xl analyzers only. for the qualitative determination of specific antibodies to hepatitis c virus (anti-hcv) in human serum or plasma samples. post mortem samples collected up to 24 hours after death have been tested and may be also used in the assay.

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48446 - hiv1/hiv2 antigen/antibody ivd, kit, chemiluminescent immunoassay - the liaison? xl murex hiv ab / ag assay uses chemiluminescence immunoassay (clia) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (hiv-1) and specific antibodies to both human immunodeficiency virus type 1 (group m and group o) and/or human immunodeficiency virus type 2 (hiv-2) in human serum or plasma samples for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (hiv-1) and specific antibodies to both human immunodeficiency virus type 1 (group m and group o) and/or human immunodeficiency virus type 2 (hiv-2) in human serum or plasma samples. post mortem samples collected up to 24 hours after death have been tested and may be also used in the assay.

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48446 - hiv1/hiv2 antigen/antibody ivd, kit, chemiluminescent immunoassay - the liaison? xl murex hiv ab / ag ht assay uses chemiluminescence immunoassay (clia) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (hiv-1) and specific antibodies to both human immunodeficiency virus type 1 (group m and group o) and/or human immunodeficiency virus type 2 (hiv-2) in human serum or plasma samples. ivds that are intended to be used in testing to provide information about infection with or exposure to human immunodeficiency viruses (hiv)

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48524 - human t-cell lymphotrophic virus 1 & 2 (htlv1 & htlv2) antibody ivd, kit, chemiluminescent immunoassay - the liaison? xl murex rechtlv-i/ii assay uses chemiluminescence immunoassay (clia) technology for the qualitative determination of specific antibodies to human t-cell lymphotropic virus (htlv) type i and type ii (anti-htlv-i and anti-htlv-ii) in human serum or plasma samples. for the qualitative determination of antibodies to human t-cell lymphotropic virus type 1 and/or type ii (htlv-i/ii) in human serum and plasma, including specimens collected up to 24 hours post mortem (non-heart beating).

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48298 - hepatitis b virus core immunoglobulin m (igm) antibody ivd, kit, chemiluminescent immunoassay - the liaison? hbc igm assay uses chemiluminescence immunoassay (clia) technology for the qualitative determination of igm immunoglobulin to hepatitis b core antigen (igm anti-hbc) in human serum or plasma samples. for the qualitative determination of igm immunoglobulin to hepatitis b core antigen (igm anti-hbc) in human serum or plasma samples.

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48304 - hepatitis b virus core total antibody ivd, kit, chemiluminescent immunoassay - the liaison? anti-hbc assay uses chemiluminescent immunoassay (clia) technology for the qualitative determination of total antibodies to hepatitis b core antigen (anti-hbc) in human serum or plasma samples. for the qualitative determination of total antibodies to hepatitis b core antigen (anti-hbc) in human serum and plasma samples, including specimens collected up to 24 hours post-mortem (non-heart beating).

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 59863 - treponema pallidum total antibody ivd, kit, chemiluminescent immunoassay - the method for determination of specific total antibodies to treponema pallidum is a one-step sandwich chemiluminescence immunoassay (clia). the liaison? treponema screen assay uses chemiluminescent immunoassay (clia) technology for the qualitative determination of specific total antibodies to treponema pallidum in human serum or plasma samples including post-mortem specimens, collected up to 24 hours after death. the test has to be performed on the liaison? analyzer family.

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48316 - hepatitis b virus surface total antibody ivd, kit, chemiluminescent immunoassay - the liaison? xl murex anti-hbs assay uses chemiluminescence immunoassay (clia) technology for the quantitative determination of antibody to hepatitis b surface antigen (anti-hbs) in human serum or plasma samples. the test has to be performed on the liaison? analyzer family. ivds for the quantitative determination of antibody to hepatitis b surface antigen (anti-hbs).

Singapore - English - HSA (Health Sciences Authority)

spd scientific pte ltd - immunology - the liaison® sars-cov-2 trimerics igg assay uses chemiluminescence immunoassay (clia) technology for the quantitative determination of anti- trimeric spike protein specific igg antibodies to sars-cov-2 in human serum or plasma samples. the assay is intended as an aid in the diagnosis of covid-19 and to support the study of the immune status of infected patients and to assess igg response against sars-cov-2 in vaccine recipients, by providing an indication of the presence of neutralizing igg antibodies against sars-cov-2. results from the liaison® sars-cov-2 trimerics igg assay should not be used as the sole basis to diagnose or exclude sars-cov-2 infection or to inform about infection status